Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Ivercar-Tuc, 2021 NCT04701710

ivermectin (n=117) vs. control (n=117)

randomized controlled trial   high risk of bias

Studied treatment

Ivermectin / lota carrageenan
Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks

Control treatment

Control

Patients

COVID-19 prophylaxis (excluding children)

Method

open-label

1 center, Argentina

Remark

NCT04422561 (Shouman), 2020 NCT04422561

ivermectin (n=228) vs. standard of care (n=112)

randomized controlled trial   high risk of bias

Studied treatment

ivermectin
two doses 72 hours apart

Control treatment

standard of care

Patients

COVID-19 prophylaxis (excluding children)

Method

open label

1 center, Egypt

Remark

Seet 2021, 2021 NCT04446104

ivermectin (n=617) vs. vitamin C (n=619)

randomized controlled trial   high risk of bias

Studied treatment

oral ivermectin (12 mg once) 42 day

Control treatment

oral vitamin C, 500 mg/day

arm study: oral hydroxychloroquine (400 mg once, followed by 200 mg/day), oral ivermectin (12 mg once), povidone-iodine throat spray (3 times/day, 270 μg/day), oral zinc (80 mg/day)/vitamin C (500 mg/day) combination, or oral vitamin C, 500 mg/day

Patients

COVID-19 prophylaxis (excluding children)

Method

open label

Singapore

cluster trial

Remark